Literature DB >> 22002566

Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours.

Karolina Holm1, Johan Staaf, Göran Jönsson, Johan Vallon-Christersson, Haukur Gunnarsson, Adalgeir Arason, Linda Magnusson, Rosa B Barkardottir, Cecilia Hegardt, Markus Ringnér, Ake Borg.   

Abstract

Amplification of chromosomal region 11q13, containing the cell cycle regulatory gene CCND1, is frequently found in breast cancer and other malignancies. It is associated with the favourable oestrogen receptor (ER)-positive breast tumour phenotype, but also with poor prognosis and treatment failure. 11q13 spans almost 14 Mb and contains more than 200 genes and is affected by various patterns of copy number gains, suggesting complex mechanisms and selective pressure during tumour progression. In this study, we used 32 k tiling BAC array CGH to analyse 94 CCND1-amplified breast tumours from sporadic, hereditary, and familial breast cancers to fine map chromosome 11q13. A set containing 281 CCND1-non-amplified breast tumours was used for comparisons. We used gene expression data to further validate the functional effect of gene amplification. We identified six core regions covering 11q13.1-q14.1 that were amplified in different combinations. The major core contained CCND1, whereas two cores were found proximal of CCND1 and three distal. The majority of the CCND1-amplified tumours were ER-positive and classified as luminal B. Furthermore, we found that CCND1 amplification is associated with a more aggressive phenotype within histological grade 2 tumours and luminal A subtype tumours. Amplification was equally prevalent in familial and sporadic tumours, but strikingly rare in BRCA1- and BRCA2-mutated tumours. We conclude that 11q13 includes many potential target genes in addition to CCND1.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22002566     DOI: 10.1007/s10549-011-1817-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  22 in total

1.  Identification of putative target genes for amplification within 11q13.2 and 3q27.1 in esophageal squamous cell carcinoma.

Authors:  Z-Z Shi; Y-Y Jiang; J-J Hao; Y Zhang; T-T Zhang; L Shang; S-G Liu; F Shi; M-R Wang
Journal:  Clin Transl Oncol       Date:  2013-11-08       Impact factor: 3.405

2.  Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling.

Authors:  Adrian Britschgi; Anke Bill; Heike Brinkhaus; Christopher Rothwell; Ieuan Clay; Stephan Duss; Michael Rebhan; Pichai Raman; Chantale T Guy; Kristie Wetzel; Elizabeth George; M Oana Popa; Sarah Lilley; Hedaythul Choudhury; Martin Gosling; Louis Wang; Stephanie Fitzgerald; Jason Borawski; Jonathan Baffoe; Mark Labow; L Alex Gaither; Mohamed Bentires-Alj
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

3.  Aberrant expression of cyclin D1 in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Sign Transduct Insights       Date:  2015-09-20

4.  Prognostic and predictive value of copy number alterations in invasive breast cancer as determined by multiplex ligation-dependent probe amplification.

Authors:  Sanaz Tabarestani; Sayyed Mohammad Hossein Ghaderian; Hamid Rezvani; Reza Mirfakhraie; Abdolali Ebrahimi; Hamid Attarian; Jahangir Rafat; Mojtaba Ghadyani; Hossein Afshin Alavi; Naser Kamalian; Afshin Rakhsha; Eznollah Azargashb
Journal:  Cell Oncol (Dordr)       Date:  2014-02-27       Impact factor: 6.730

5.  Whole genome DNA methylation signature of HER2-positive breast cancer.

Authors:  Breezy M Lindqvist; Sten Wingren; Parviz B Motlagh; Torbjörn K Nilsson
Journal:  Epigenetics       Date:  2014-07-08       Impact factor: 4.528

6.  Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers.

Authors:  Zhishuang Li; Jingjing Cui; Qiong Yu; Xiaojuan Wu; Aifeng Pan; Li Li
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

7.  A test for comparing two groups of samples when analyzing multiple omics profiles.

Authors:  Nimisha Chaturvedi; Jelle J Goeman; Judith M Boer; Wessel N van Wieringen; Renée X de Menezes
Journal:  BMC Bioinformatics       Date:  2014-07-08       Impact factor: 3.169

8.  Tumor characterization and stratification by integrated molecular profiles reveals essential pan-cancer features.

Authors:  Zhaoqi Liu; Shihua Zhang
Journal:  BMC Genomics       Date:  2015-07-07       Impact factor: 3.969

9.  CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer.

Authors:  Mark D M Leiserson; Hsin-Ta Wu; Fabio Vandin; Benjamin J Raphael
Journal:  Genome Biol       Date:  2015-08-08       Impact factor: 13.583

10.  Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.

Authors:  Sophie Lehn; Nicholas P Tobin; Andrew H Sims; Olle Stål; Karin Jirström; Håkan Axelson; Göran Landberg
Journal:  BMC Cancer       Date:  2014-02-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.